NAD evaluates Ganeden dietary supplement claims

NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Thursday released its review of advertising claims for Ganeden Biotech Digestive Advantage Irritable Bowel Syndrome and Crohn’s & Colitis dietary supplements, suggesting that Ganeden should discontinue certain claims against those products for lack of clinical support.

Similarly, NAD found that the advertiser’s own discontinuance of its claims that in a recent clinical study, patients with Crohn’s noted a 40 percent reduction in episodes of diarrhea and “once daily” was proper. NAD also declined to review claims that Ganeden’s products are “medical foods” because that issue is currently under review at the Food and Drug Administration.  

However, NAD did agree that Ganeden’s claim that their products were revolutionary was substantiated.

In its advertiser’s statement, Ganeden noted its appreciation for NAD’s review and NAD’s finding regarding the claim that their product is “revolutionary.”

 Further, Ganeden said, while it believes that “the testimonials state appropriate claims for these products as medical foods and, therefore, their status should also have been deferred, the company will discontinue these testimonials and will take the NAD’s recommendations into consideration in future use of testimonials for these products.”